Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany

Enno Schmidt*, Detlef Zillikens

*Korrespondierende/r Autor/-in für diese Arbeit
8 Zitate (Scopus)

Abstract

In Germany, more than 2000 new patients per year have been calculated to be diagnosed with autoimmune blistering diseases. In a recent survey, the most frequently applied treatment regimens for bullous pemphigoid were class IV topical corticosteroids and oral prednisolone 0.5 mg or 1.0 mg/kg/d plus dapsone or azathioprine. For pemphigus, two-thirds of the clinics applied oral prednisolone at doses of 1.0 mg or 1.5 mg/kg/d and in more than 80% of departments, azathioprine was chosen as concomitant immunosuppressant. High-dose intravenous immunoglobulin, rituximab, and immunoadsorption are increasingly used for refractory patients. Treatment and diagnostic costs are covered by the health insurances when applied according to published expert recommendations.
OriginalspracheEnglisch
ZeitschriftDermatologic Clinics
Jahrgang29
Ausgabenummer4
Seiten (von - bis)663-671
Seitenumfang9
ISSN0733-8635
DOIs
PublikationsstatusVeröffentlicht - 01.10.2011

Fingerprint

Untersuchen Sie die Forschungsthemen von „Diagnosis and Treatment of Patients with Autoimmune Bullous Disorders in Germany“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren